Comment from Critical Path Institute

Summary: The Critical Path Institute (C-Path), a nonprofit organization, supports the FDA's draft guidance on the Plausible Mechanism Framework for developing individualized therapies. They recommend providing greater clarity on statutory alignment, evidentiary expectations for mechanistic data, the role of biomarkers, and the integration of natural history data and quantitative modeling to ensure consistent regulatory decision-making.